Large pharmaceutical and diagnostic players companies have been acquiring emerging gene and cell therapy companies with promising drug pipelines or drug approvals, some with limited revenue.
In March 2019, Thermo Fisher Scientific agreed to pay $1.7b to acquire Brammer Bio, which offers pre-clinical and analytical development, process optimization, and analytical qualification services, as well as clinical and commercial drug substances, and formulated drug products. In February 2019, Roche agreed to pay $4.8b for Spark Therapeutics, which offers Luxturna, a gene therapy for eye disease and four products in clinical trials. And in January, Eli Lily announced to purchase Loxo Oncology for $8b. The company also has three main pipeline products for cancers caused by a single genetic mutation.
Keywords: Healthcare Investment Banking, Healthcare M&A, Healthcare mergers